SOPHiA GENETICS SA
SOPH Nasdaq· Services-Computer Processing & Data Preparation
Last close · Oct 26, 2026
$7.52
KIRA · Stoqly’s AI analyst, in plain words
- SOPHiA GENETICS SA had $77.3M of revenue in fiscal 2025, up 18.6% on the year before. Over five years, revenue changed +22.2% a year on average.
- Its operating margin was −91.8%, up 10.4 pts: of every 100 in sales, about −92 is left after running the business.
- SOPHiA GENETICS SA lost $79.0M in fiscal 2025.
- Free cash flow was −$36.5M in fiscal 2025, −47.2% of revenue.
- SOPHiA GENETICS SA has $22.6M more cash than debt.
Market cap
$508M
P/E
—
Revenue
$77.3M
Net income
−$79.0M
Free cash flow
−$36.5M
Operating margin
−91.8%
SOPHiA GENETICS SA in 30 seconds · fiscal 2025
Are sales growing?
+18.6%
Yes. Sales grew 18.6% last year.
Does it make a profit?
−102.2%
No. It lost money last year.
Does profit turn into cash?
−47.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What SOPHiA GENETICS SA does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 3, 2026
- Legal name
- SOPHiA GENETICS SA
- CIK
- 0001840706
SOPHiA GENETICS SA · SOPH
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $40.5M | $47.6M | $62.4M | $65.2M | $77.3M |
| Revenue growth | 42.4% | 17.6% | 31.1% | 4.5% | 18.6% |
| Net interest income | −$0.6M | $0.7M | $4.0M | — | — |
| Gross margin | 62.4% | 65.7% | 68.8% | 67.4% | 67.4% |
| Operating margin | −176.7% | −184.7% | −120.0% | −102.1% | −91.8% |
| Net income | −$73.7M | −$87.4M | −$79.0M | −$62.5M | −$79.0M |
| Net margin | −182.1% | −183.9% | −126.6% | −95.9% | −102.2% |
| Diluted EPS | −$1.33 | −$1.36 | −$1.22 | −$0.95 | −$1.17 |
| Cash | |||||
| Cash from operations | −$57.9M | −$70.1M | −$53.2M | −$44.5M | −$35.9M |
| Capital expenditure | $2.7M | $4.1M | $1.5M | $0.2M | $0.6M |
| Free cash flow | −$60.6M | −$74.2M | −$54.7M | −$44.8M | −$36.5M |
| FCF margin | −149.9% | −156.0% | −87.7% | −68.7% | −47.2% |
| Share count change | 30.6% | 15.9% | 1.0% | 2.0% | 2.2% |
| Debt and strength | |||||
| Cash and short-term investments | $193M | $161M | $123M | $80.2M | $70.3M |
| Debt incl. finance leases | $0.0M | — | $0.0M | $13.2M | $47.7M |
| Shareholders' equity | $275M | $200M | $151M | $96.5M | $47.1M |
| Current ratio | 9.9x | 7.3x | 4.2x | 3.7x | 2.0x |
| Interest coverage | −108.6x | −137.4x | −127.3x | −34.8x | −15.6x |
| Returns and quality | |||||
| Return on capital | −68.5% | — | −209.7% | −178.3% | −227.8% |
| Return on equity | −39.2% | −36.8% | −44.9% | −50.4% | −110.0% |
| Return on tangible equity | −28.4% | −48.5% | −63.6% | −92.6% | −702.0% |
| Piotroski F-score | 5 | 3 | 3 | 2 | 2 |
| Altman Z'' | 8.0 | 3.0 | −1.9 | −7.3 | −10.9 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$5.2M
10 insiders
Of sales under plans
100%
$5.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
SOPHiA GENETICS SA · SOPH
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.52 a share, the company is worth $508M.
Source: SEC EDGAR XBRL filings (CIK 0001840706). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.